Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Fulcrum Therapeutics Inc
(NQ:
FULC
)
9.170
+0.380 (+4.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,310,017
Open
8.860
Bid (Size)
8.810 (2)
Ask (Size)
9.200 (10)
Prev. Close
8.790
Today's Range
8.810 - 9.250
52wk Range
3.140 - 13.70
Shares Outstanding
61,758,994
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
August 19, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+27.18%
+27.18%
1 Month
+6.13%
+6.13%
3 Month
+18.48%
+18.48%
6 Month
-5.76%
-5.76%
1 Year
+66.88%
+66.88%
More News
Read More
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
May 13, 2024
Via
Benzinga
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
April 12, 2024
Via
Investor Brand Network
8 Health Care Stocks With Whale Alerts In Today's Session
August 01, 2024
Via
Benzinga
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
July 31, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
July 24, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
July 16, 2024
Via
Benzinga
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
June 12, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
June 11, 2024
Via
Benzinga
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
June 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 13, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
Via
InvestorPlace
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 09, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
May 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
April 15, 2024
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
March 29, 2024
Via
Benzinga
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
March 28, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.